EpiCypher

Executive Summary

EpiCypher is a privately held biotechnology company based in Durham, North Carolina, focused on providing innovative tools and services for epigenetics and chromatin biology. Founded in 2012, the company has established itself as a key research partner by developing cutting-edge platforms for genomic mapping, nucleosome analysis, and chromatin profiling. These tools enable scientists to accelerate discoveries in gene regulation, disease mechanisms, and therapeutic development. EpiCypher's product portfolio includes proprietary assays, antibodies, and nucleosome standards that address critical needs in the study of epigenetic modifications. While the company operates in a competitive landscape, its specialized focus on chromatin biology and high-quality reagents positions it well within the growing epigenetics market. With a strong emphasis on supporting both academic and pharmaceutical research, EpiCypher is poised to benefit from the increasing demand for epigenetic insights in drug discovery and personalized medicine.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation nucleosome profiling platform70% success
• Q4 2026Strategic partnership with a major pharmaceutical company for epigenetic drug target discovery50% success
• Q3 2026Publication of validation data for novel chromatin modification antibodies in a high-impact journal80% success